

- Coeur en sabot*, 1527
 Coffee worker's lung, 1681t
 Cogan's syndrome, 1638, 2192, 2204
 Cognitive behavioral therapy (CBT)
 for alcohol use disorder, 2728
 for back pain, 120
 for chronic fatigue syndrome, 464e-2-3
 for depression, 2717
 for fatigue, 153
 for female sexual dysfunction, 331
 for fibromyalgia, 2240
 for glossodynia, 239
 for insomnia, 191
 for metabolic syndrome, 2453
 for obesity, 2396
 for PTSD, 471e-5
 Cognitive dysfunction
 alcohol use and, 2724
 assessment of, 37e-1v
 caring for patient with, 184
 delirium and, 166
 hypertension-related, 1615
 in MS, 2663
 treatment of, 444e-11f
 Cognitive evoked potentials, 442e-3
 Cognitive function
 assessment of, 167
 postmenopausal hormone therapy and, 6e-2, 2384t, 2385-2386
 Cognitive rehabilitation procedures, 184
 Cogwheel rigidity, 2538
 Cohen's syndrome, 415e-5t
COL1A1/2 gene mutations
 in chondrodysplasias, 2511
 in Ehlers-Danlos syndrome, 2510t, 2511
 in osteogenesis imperfecta, 435, 2454, 2508t, 2509
COL4A4/5 gene mutations, 2514
COL17A1 gene mutations, 434
 Colchicine
 for acute idiopathic pericarditis, 1573
 adverse effects of, 2214
 alopecia, 354
 cobalamin malabsorption, 644t
 diarrhea, 269, 1573, 2234
 myopathy, 462e-20, 462e-20t, 2199, 2218t
 neuropathy, 2687t, 2688
 for Behçet's syndrome, 2194
 for calcium apatite deposition disease, 2236
 for calcium pyrophosphate deposition disease, 2236
 contraindications to, 1573
 drug interactions of, 2235
 for familial Mediterranean fever, 723, 2214
 for fever of unknown origin, 141
 for gout, 2234
 Cold abscess, 423
 Cold agglutinin disease, 659
 Cold exposure, cyanosis in, 249
 Cold-induced autoinflammatory syndrome, familial, 422
 Cold sore, 233
 Cold-stimulus headache, 2597
 Cold urticaria, 363, 363t, 2118-2119
 Colectomy, 274, 479, 539, 861
 Colesevelam, 2415, 2448t, 2449
 Colestipol, 2448t, 2449, 2453
 Colic, biliary. *See* Biliary colic
 Colic acid, 2076
 Colistin. *See* Polymyxin E (colistin)
 Colitis
 amebic, 1365
 bleeding in, 277
 CMV, in HIV infection, 1257
 collagenous, 270, 1957
 colonoscopy in, 1881, 1882f, 1899f
 cord-blood stem cell-associated, 772
 in Crohn's disease, 1953
 diarrhea in, 270
 diversion, 1957
 etiology of, 1882f
 vs. IBD, 1956-1957
 ischemic. *See* Ischemic colitis
 lymphocytic, 1957
 microscopic, 270
 primary immune deficiency diseases and, 2113
 pseudomembranous, 855, 858, 858f, 1882f. *See also* *Clostridium difficile*-associated disease
 sexually acquired, 881
 Collagen
 autoantibodies to, 372e-24t
 in connective tissues, 2505
 fibrillar, 2506-2507, 2506f
 Collagenoma, 2336t, 2340
 Collagenous colitis, 1957
 Collagenous sprue, 1942
 Collagen type IV-3 α -chain, 372e-24t
 Collagen vascular disease, 47e-4, 1467t, 1911
 Collecting duct
 disorders involving, 332e-7t
 functions of, 332e-5f, 332e-6f, 332e-8-9
 tumors of, 578, 578t. *See also* Renal cell carcinoma (RCC)
 Collectins, 145e-5, 372e-2
 Colles' fracture, 2488f
 Collier's sign, 210
 Colloid cysts, 603
 Colloid goiter, 2301
 Colon
 bleeding from, 277
 blood supply to, 1979, 1979f
 cathartic, 273
 diverticula of. *See* Diverticular disease
 functions of, 1875, 1933-1934
 length of, 1933
 obstruction of. *See* Intestinal obstruction
 physiology of, 264-265, 264t
 polyps of, 482, 1897, 1897f. *See also* Colorectal cancer
 storage and salvage in, 265
 transit time, measurement of, 273
 Colonic obstruction. *See* Intestinal obstruction
 Colonic pseudoobstruction. *See* Intestinal pseudoobstruction
 Colonization, 145e-1
 Colonization factors, 145e-2
 Colonoscopy, **1881**
 after polyp removal, 538
 in colitis, 1881, 1882f
 for colorectal cancer screening
 adenocarcinoma appearance in, 1883f
 in average-risk patients, 29t, 481t, 482, 1898t
 costs of, 30
 vs. flexible sigmoidoscopy, 540-541
 in inflammatory bowel disease, 1898t
 with personal or family history, 1898t
 polyp appearance in, 1877, 1882f, 1883f, 1897f, 1899f
 sensitivity of, 1881
 strategies for, 1897-1898
 in constipation, 273
 in diarrhea, 267, 272
 in gastrointestinal bleeding, 278-279
 indications for, 1878, 1879t
 in intestinal ischemia, 1980
 in nausea and vomiting, 260
 open-access, 1900
 patient preparation for, 1900
 polyp removal during, 346e-1v
 in ulcerative colitis, 1952, 1953f
 virtual, 540, 1898-1899, 1899f
 Colon stem cells, 453t
 Colony-stimulating factors, 413
 Colorado tick fever virus, 1306t, 1319
 Color anomia, 179, 197
 Color blindness, 197, 2629
 Colorectal cancer, **537**
 adenomatous polyps and, 537-538
 back pain in, 118
 carcinoma of unknown primary and, 120e-4
 clinical features of, 540-541, 541f
 deaths from, 467t, 469f, 471t, 537
 epigenetic silencing in, 102e-7
 etiology of, 538-539, 538t
 genetic considerations in
 chromosome abnormalities, 101e-1f, 101e-2t, 101e-3t, 101e-5, 537-538
 familial syndromes, 101e-1f, 101e-5, 101e-6t, 538-539, 538t
 genomewide profiling, 101e-9f
 IBD and, 1964-1965, 1965f
 incidence of, 467t, 468, 468f, 471t, 537
 infections in, 486t, 539
 insulin resistance and, 538
 lifetime cumulative risk of, 27t
 metastatic, 542, 553, 604t
 pathogenesis of, 101e-1f, 537-538
 postmenopausal hormone therapy and, 2384t, 2385
 prevention of, 476, 477-478, 479, 539
 prognosis of, 541-542, 542f, 542t
 recurrence of, 542
 risk factors for, 538-539, 538t
 screening for. *See also* Colonoscopy, for colorectal cancer screening
 benefits of, 27, 30, 540
 in elderly, 84
 in inflammatory bowel disease, 1898t
 with personal or family history, 1898t
 recommendations for normal-risk adults, 29t, 481t, 482, 540-541, 1898t
 techniques of, 540-541, 540t
 spread of, 542
 staging of, 541-542, 542f
 treatment of, 543-544
 biologic therapy, 102e-5t, 103e-21, 103e-21t, 543
 chemotherapy, 543
 endoscopic dissection, 346e-1v, 1887f
 endoscopic stent placement, 1895f
 late consequences of, 624t
 radiation therapy, 543
 surgery, 542-543
 targeted chemotherapy, 103e-19, 543
 tumor markers in, 473t
 Color flow Doppler, 270e-2, 270e-2f. *See also* Echocardiography
 Color vision, assessment of, 197
 Coltiviruses, 1305, 1306t
 Coltivirus infections, 1306t, 1319
 Coma, **1771**
 anatomy of, 329e-1v, 1771-1772
 approach to the patient
 brainstem reflexes, 1774-1775, 1774f
 history, 1773
 level of arousal, 1774
 neurologic examination, 41e-1v, 1773-1774
 physical examination, 329e-1v, 1773
 brain death determination in, 1776
 definition of, 1771
 diagnosis of, 329e-1v, 442e-2, 1772f, 1775
 differential diagnosis of, 1775-1776, 1776t
 in metabolic disorders, 1772-1773
 pathophysiology of, 1772-1773, 1772f
 prognosis of, 1777
 treatment of, 1776-1777
 Coma bullae, 361t, 362
 Combat veterans. *See* War veterans
 Combination antiretroviral therapy (cART). *See also specific drugs*
 action of, 214e-5
 adverse effects of, 6e-4, 1274-1275t, 2030, 2689
 in developing countries, 12, 13f
 entry inhibitors, **1275t**, 1277f, 1280f, 1281
 formulations of, 1277t
 in HBV virus infection, 1273
 indications for changing, 1282, 1282t
 initiation of, 770, 1282, 1282t
 integrase inhibitors, **1275t**, 1277f, 1280f, 1281
 principles of, 1273, 1281-1283, 1282t
 protease inhibitors, **1275t**
 action of, 1278
 adverse effects of, 1278, 2218t, 2422
 drug interactions of, 34t, 41, 798, 1278
 for HCV infection, 2044, 2045-2046t, 2046-2047
 for HIV infection, 1275t, 1278